Preparations and methods for ameliorating or reducing presbyopia

• US 8,455,494 B2
• Filed: 09/06/2012
• Issued: 06/04/2013
• Est. Priority Date: 05/22/2009
• Status: Active Grant

• Current Assignee: Visus Therapeutics, Inc.
• Original Assignee: Hek Development, LLC
• Inventors: Kaufman, Herbert E.
• Primary Examiner(s): Padmanabhan, Sreeni
• Assistant Examiner(s): RAMACHANDRAN, UMAMAHESWARI
• Application Number:
  US13/605,302
• Publication Number:
  US 20120329805A1
• Time in Patent Office: 271 Days
• Field of Search: 514/642, 514/912
• US Class Current: 514/249
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/27 of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
• CPC Class Codes: A61K 31/325 Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof thiurams A61K31/145
• CPC Class Codes: A61K 31/498 Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia

Abstract

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Claims

1. A method for ameliorating or reducing presbyopia of a patient, comprising administering to only a single eye of said patient an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine, or pharmaceutically acceptable salts thereof, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

2. The method of claim 1, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.

3. A method of producing ocular miosis in a single eye of a subject which comprises administering to the eye an amount of an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine, or pharmaceutically acceptable salts thereof, effective to produce ocular miosis, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

4. The method of claim 3, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.

5. A method for ameliorating or reducing presbyopia of a patient, comprising administering to one eye of the patient a therapeutically effective amount of an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine, or pharmaceutically acceptable salts thereof, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

6. The method of claim 5, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.

7. A method of ameliorating, reducing or eliminating a vision defect a patient comprising administering to only a single eye of the patient a therapeutically effective amount of an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine, or pharmaceutically acceptable salts thereof, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

8. The method of claim 7, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.

9. A method of improving focus and/or correcting refractive errors of a patient comprising administering to a single eye of the patient a therapeutically effective amount of an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine, or pharmaceutically acceptable salts thereof, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

10. The method of claim 9, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.

11. A method of treating presbyopia in a patient in need of treatment thereof comprising administering an effective amount of an ophthalmic preparation comprising a therapeutically effective amount of carbachol, or pharmaceutically acceptable salts thereof, and brimonidine to a single eye of a patient thereby leaving the other eye untreated, wherein carbachol is present in the preparation in an amount of 1.5-5% and brimonidine is present in an amount of 0.05-3.0%.

12. The method of claim 11, wherein carbachol is present in the preparation in an amount of 2.25-3.5%.